questionText: To ask the Secretary of State for Health and Social Care, what guidance is issued to clinicians on discussing in advance with patients, and where appropriate their families, how treatment should be managed if severe impulse control disorders develop while taking dopamine agonists, including the option of recording the patient’s wishes about dose reduction or discontinuation.
answerText: The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease...
heading: Drugs: Side Effects